Presentation is loading. Please wait.

Presentation is loading. Please wait.

Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients Saul Shiffman.

Similar presentations


Presentation on theme: "Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients Saul Shiffman."— Presentation transcript:

1 Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients
Saul Shiffman

2 Outcome of Smoking Cessation without Treatment
47% report trying to quit annually 13% of unaided quit efforts don’t last 24 h Sustained unaided quit rate <3%

3 Pharmacologic treatment
Behavioral treatment Pharmacologic treatment

4 Behavioral Treatment Aimed at assisting behavior change
Practical psycho-educational approach Based on cognitive-behavioral treatment principles “Multi-component” mix dominates Few/no “brand-name” differentiated treatment approaches Little/no content innovation in 20 years

5 Active Ingredients in Behavioral Programs
Information Motivation enhancement Encouragement Support Planning & problem-solving Tips & techniques Medication support Process orientation Structure Conceptual Temporal A specific, step-by-step, pathway to quitting Contact, engagement, caring Lifestyle change

6 Effectiveness of Behavioral Treatment Components
Guess which treatment is no longer in current use * Significantly better than nothing Source: AHRQ analysis: 2000

7 More is Better Source: AHRQ analysis: 2000

8 Developments in Behavioral Treatment
Little/no content innovation Innovations in delivery modality & dissemination Channels Media Providers Packaging Duration

9 The Old & New Models of Behavioral Treatment
Old way New way Approach Cognitive-behavioral Medium Face-2-face Phone, web Delivery model Central De-centralized Provider Semi-Pro Para-pro, computer Scripting Ad-lib Scripted Intensity High Low-Medium Medication Negative Integrate

10 Some Low-Intensity, Convenient Forms Are Ineffective
Source: AHRQ analysis: 2000

11 Effectiveness Rises with Intensity
Source: AHRQ analysis: 2000

12 Targeting to Groups By gender, ethnicity, age, disease, etc, etc
No evidence they require different approaches Targeted materials may be more appealing Situations that affect the challenge & need may need different approach e.g., pregnancy, acute abstinence in hospital

13 Tailoring to Individuals
One size does not fit all Assess user Tailor content, emphasis, sequence to individual characteristics and needs Model what a counselor would do Greater utilization, satisfaction Improved efficacy

14 Pharmacologic treatment
Behavioral treatment Pharmacologic treatment

15 Pharmacological Treatment
Meant to address dependence-related symptoms Nicotine Replacement Therapy (NRT) Patch Gum Lozenge Puffer Nasal spray Bupropion New compounds, approaches coming (Frank Vocci) OTC

16 All Medications Effective; About Equally Effective
Studies vary in populations, behavioral intervention, and length of follow-up Source: AHRQ analysis: 2000

17 Combining Medications Enhances Efficacy
No combination approved by FDA gum, puffer, nasal spray Source: AHRQ analysis: 2000

18 Innovation in Dissemination: OTC Marketing Increased Utilization
Zyban intro Nasal Spray Patch mania OTC switch Estimated Assisted Quit Attempts (in thousands) Burton et al, MMWR, 2000

19 Pharmacologic treatment
Behavioral treatment Pharmacologic treatment

20 Pharmacological & Behavioral Treatments: Additive Effects
RR = 1.9 Pharm RR = 1.5 Beh RR = 1.7 Beh RR = 1.9 Silagy meta-analysis

21 Treatment Options: Approximate Effectiveness

22 Impact of Treatment Depends on Utilization
Impact (# of quits) = Efficacy (% quit) X Utilization (# using method)

23 Treatment Options: Most Effective are Least Used
Least effective methods most used 1% 8% 1% 11% 7% 72%

24 Even Among NRT Users Compliance is Poor – and it Matters
Average nicotine gum use ~ 4/day

25 Status of Cessation Treatment and Goals for Change
Efficacy Low High Reach Present

26 Barriers to Treatment Use
Behavioral Tx Disconnect on mechanism Don’t see a need Injury to esteem Doubt efficacy Cost Mostly non-cash Pharmacological Tx Disconnect on mechanism Don’t see a need Injury to esteem Doubt efficacy Doubt safety Cost Mixed empirical support

27 We Are Reaching Only The Tip of the Iceberg
Actually trying to quit 5% Not currently interested in quitting 56% Interested in quitting, not ready to quit now 26% Preparing to try quitting 13% Our Church of Perpetual Abstinence Sources: NHIS 2000, DiClemente et al, 1991

28 Building Demand “Build it, they will come”
Marketing: product, positioning, packaging, promotion Figure out what people want Explain what it is Explain why they need it Make it pleasant, palatable, effective Make it cool Different strokes for different folks Make it, attractive, accessible, & convenient Promote it (repeatedly) Maintain a continuing relationship & system of care – not!

29 NOT!


Download ppt "Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients Saul Shiffman."

Similar presentations


Ads by Google